FMP
Zoetis Inc.
ZTS
NYSE
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
157.44 USD
1.79 (1.14%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
2.32B
2.39B
2.36B
2.19B
707M
701M
703M
680M
1.61B
1.69B
1.66B
1.51B
845M
732M
752M
709M
186M
167M
171M
162M
625M
565M
581M
547M
0
0
0
0
0
0
0
0
34M
0
2M
-5M
765M
920M
906M
801M
-33M
-46M
-161M
-91M
732M
874M
780M
747M
151M
182M
156M
148M
581M
682M
624M
599M
1.28
1.51
1.37
1.31
1.28
1.5
1.37
1.31
450.5M
452.9M
455.5M
458M
451.1M
453.5M
456M
458.8M
911M
1.06B
1.03B
927M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
11.81B
11.12B
10.7B
10.29B
581M
682M
624M
599M
-553M
-433M
-533M
-339M
-194M
-197M
-197M
-198M
11.97B
11.81B
11.12B
10.7B
-585M
52M
-302M
-136M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
3.61B
3.52B
3.42B
3.48B
123M
121M
127M
126M
-216M
-167M
-132M
-140M
3.7B
3.57B
3.43B
3.49B
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-20M
5M
-20M
0
2.74B
2.74B
2.76B
2.76B
2.72B
2.74B
2.74B
2.76B
All figures are in USD.